1. Academic Validation
  2. Exploring Biological Targets of Magnolol and Honokiol and their Nature-Inspired Synthetic Derivatives: In Silico Identification and Experimental Validation of Estrogen Receptors

Exploring Biological Targets of Magnolol and Honokiol and their Nature-Inspired Synthetic Derivatives: In Silico Identification and Experimental Validation of Estrogen Receptors

  • J Nat Prod. 2024 Nov 22;87(11):2568-2579. doi: 10.1021/acs.jnatprod.4c00634.
Annachiara Tinivella 1 Jerome C Nwachukwu 2 Luca Pinzi 1 Maria Antonietta Dettori 3 Davide Fabbri 3 Paola Carta 3 Kendall W Nettles 2 Giulio Rastelli 1
Affiliations

Affiliations

  • 1 Department of Life Sciences, University of Modena and Reggio Emilia, Via Campi 103, 41125 Modena, Italy.
  • 2 Department of Immunology and Microbiology, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, Florida 33458, United States.
  • 3 Institute of Biomolecular Chemistry of CNR, Traversa La Crucca 3, 07100 Sassari, Italy.
Abstract

In this work, we describe the results of a computational investigation aimed at identifying potential biological targets of honokiol, magnolol and a series of synthetic prodrug derivatives obtained through esterification of the free hydroxyl groups. The ligand-based and structure-based analyses revealed that these compounds potentially interact with several biological targets, some of which are known while Others are new. Honokiol, magnolol, and three of the newly synthesized derivatives may bind to estrogen receptors ERα and ERβ. Biological testing confirmed that these compounds modulate estrogen-regulated transcriptional activity mediated by ERα or ERβ with potencies in the nanomolar range. In particular, magnolol and one of its derivatives (10) behaved as partial antagonists of ERα and ERβ, while compounds 8 and 11 behaved as partial agonists. These findings validate the computational predictions and shed light on the mechanism of action of these natural compounds, paving the way for further investigation in the context of targeted therapies.

Figures
Products